Details

Autor(en) / Beteiligte

• Corbett, Kizzmekia S
• Edwards, Darin K
• Leist, Sarah R
• Abiona, Olubukola M
• Boyoglu-Barnum, Seyhan
• Gillespie, Rebecca A
• Himansu, Sunny
• Schäfer, Alexandra
• Ziwawo, Cynthia T
• DiPiazza, Anthony T
• Dinnon, Kenneth H
• Elbashir, Sayda M
• Shaw, Christine A
• Woods, Angela
• Fritch, Ethan J
• Martinez, David R
• Bock, Kevin W
• Minai, Mahnaz
• Nagata, Bianca M
• Hutchinson, Geoffrey B
• Wu, Kai
• Henry, Carole
• Bahl, Kapil
• Garcia-Dominguez, Dario
• Ma, LingZhi
• Renzi, Isabella
• Kong, Wing-Pui
• Schmidt, Stephen D
• Wang, Lingshu
• Zhang, Yi
• Phung, Emily
• Chang, Lauren A
• Loomis, Rebecca J
• Altaras, Nedim Emil
• Narayanan, Elisabeth
• Metkar, Mihir
• Presnyak, Vlad
• Liu, Cuiping
• Louder, Mark K
• Shi, Wei
• Leung, Kwanyee
• Yang, Eun Sung
• West, Ande
• Gully, Kendra L
• Stevens, Laura J
• Wang, Nianshuang
• Wrapp, Daniel
• Doria-Rose, Nicole A
• Stewart-Jones, Guillaume
• Bennett, Hamilton
• Alvarado, Gabriela S
• Nason, Martha C
• Ruckwardt, Tracy J
• McLellan, Jason S
• Denison, Mark R
• Chappell, James D
• Moore, Ian N
• Morabito, Kaitlyn M
• Mascola, John R
• Baric, Ralph S
• Carfi, Andrea
• Graham, Barney S

Titel

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Ist Teil von

• Nature (London), 2020-10, Vol.586 (7830), p.567-571

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity . This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant SARS-CoV-2 as well as CD8 T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy.